<DOC>
	<DOC>NCT02737475</DOC>
	<brief_summary>The purpose of the study is to determine safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti tumor activity of BMS-986178 when administered alone or in combination with Nivolumab or Ipilimumab in subjects with advanced solid tumors.</brief_summary>
	<brief_title>Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Patients must have at least 1 standard treatment regimen in the advanced, recurrent or metastatic setting ECOG (Eastern Cooperative Oncology Group) 01 Men and women 18 years old or older At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1 Known central nervous system metastases or central nervous system as the only source of disease Concomitant malignancies Active known or suspected autoimmune disease Uncontrolled or significant cardiovascular disease Major surgery less than 4 weeks before the start of the study Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>